Illumina (NASDAQ:ILMN) will post its quarterly earnings results after the market closes on Monday, January 29th. Analysts expect Illumina to post earnings of $1.19 per share for the quarter. Illumina has set its FY17 guidance at $3.73-3.78 EPS.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.97 EPS. On average, analysts expect Illumina to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Illumina (NASDAQ:ILMN) opened at $243.55 on Monday. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $35,560.00, a price-to-earnings ratio of 45.95, a price-to-earnings-growth ratio of 3.27 and a beta of 0.79. Illumina has a 12-month low of $156.50 and a 12-month high of $248.97.
In related news, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $243.72, for a total value of $3,655,800.00. Following the sale, the director now directly owns 449,201 shares of the company’s stock, valued at $109,479,267.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $207.88, for a total value of $334,478.92. Following the completion of the sale, the senior vice president now directly owns 7,217 shares in the company, valued at $1,500,269.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 154,671 shares of company stock worth $33,626,228. 0.89% of the stock is currently owned by insiders.
WARNING: “Illumina (ILMN) Set to Announce Earnings on Monday” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/22/illumina-ilmn-set-to-announce-earnings-on-monday.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.